DARE - Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate Seeks Regulatory Approval | Benzinga
Bayer AG (OTC:BAYRY) (OTC:BAYZF) will present detailed results from the Phase 3 studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms (hot flashes) associated with menopause compared to placebo.
The company released the topline data showing elinzanetant met all four primary endpoints in both studies.
These data will be presented at the 2024 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.
Related: German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits.
Elinzanetant met all ...